Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Bernard CouliePresident and CEO | Pliant TherapeuticsPLRX | Open-market sale10b5-1 plan | 01/20 | 01/22 | 89,375 sh | $1.28 | $114,400 | −15.0% |
Pliant TherapeuticsPLRX | Open-market sale10b5-1 plan | 01/20 | 01/22 | 24,002 sh | $1.28 | $30,722.56 | −7.5% | |
Lily CheungChief Human Resource Officer | Pliant TherapeuticsPLRX | Open-market sale10b5-1 plan | 01/20 | 01/22 | 7,534 sh | $1.28 | $9,643.52 | −14.4% |
Minnie KuoCOO | Pliant TherapeuticsPLRX | Open-market sale10b5-1 plan | 01/20 | 01/22 | 6,917 sh | $1.28 | $8,853.76 | −15.5% |
Pliant TherapeuticsPLRX | Open-market sale10b5-1 plan | 25/01/17–25/01/22 | 25/01/22 | 23,500 sh2 trades | $11.11avg. | $261,051.7 | −25.0% | |
Eric LefebvreChief Medical Officer | Pliant TherapeuticsPLRX | Open-market sale10b5-1 plan | 25/01/17 | 25/01/22 | 18,478 sh | $11.20 | $206,953.6 | −8.7% |
Hans HullChief Business Officer | Pliant TherapeuticsPLRX | Open-market sale10b5-1 plan | 25/01/17 | 25/01/22 | 15,936 sh | $11.20 | $178,483.2 | −7.0% |
Bernard CouliePresident and CEO | Pliant TherapeuticsPLRX | Open-market sale10b5-1 plan | 25/01/17 | 25/01/22 | 52,419 sh | $11.20 | $587,092.8 | −10.9% |
Pliant TherapeuticsPLRX | Open-market sale10b5-1 plan | 25/01/17 | 25/01/22 | 20,148 sh | $11.20 | $225,657.6 | −7.1% | |
Lily CheungChief Human Resource Officer | Pliant TherapeuticsPLRX | Open-market sale10b5-1 plan | 25/01/17 | 25/01/22 | 3,740 sh | $11.20 | $41,888 | −13.2% |
Eric LefebvreChief Medical Officer | Pliant TherapeuticsPLRX | Open-market sale10b5-1 plan | 24/07/10 | 24/07/12 | 12,319 sh | $11.56 | $142,407.64 | −5.5% |
Hans HullChief Business Officer | Pliant TherapeuticsPLRX | Open-market sale10b5-1 plan | 24/07/10 | 24/07/12 | 9,900 sh | $11.56 | $114,444 | −4.2% |
Bernard CouliePresident and CEO | Pliant TherapeuticsPLRX | Open-market sale10b5-1 plan | 24/07/10 | 24/07/12 | 38,710 sh | $11.56 | $447,487.6 | −7.4% |
Pliant TherapeuticsPLRX | Open-market sale10b5-1 plan | 24/07/10 | 24/07/12 | 10,911 sh | $11.56 | $126,131.16 | −3.7% | |
Mike OuimetteGeneral Counsel & Corp. Sec'y | Pliant TherapeuticsPLRX | Open-market sale10b5-1 plan | 24/07/10 | 24/07/12 | 7,656 sh | $11.56 | $88,503.36 | −7.5% |
Eric LefebvreChief Medical Officer | Pliant TherapeuticsPLRX | Open-market sale10b5-1 plan | 24/01/17 | 24/01/19 | 10,295 sh | $17.23 | $177,382.85 | −6.2% |
Hans HullChief Business Officer | Pliant TherapeuticsPLRX | Open-market sale10b5-1 plan | 24/01/17 | 24/01/19 | 9,786 sh | $17.23 | $168,612.78 | −5.0% |
Bernard CouliePresident and CEO | Pliant TherapeuticsPLRX | Open-market sale10b5-1 plan | 24/01/17 | 24/01/19 | 25,721 sh | $17.23 | $443,172.83 | −7.5% |
Pliant TherapeuticsPLRX | Open-market sale10b5-1 plan | 24/01/17 | 24/01/19 | 9,781 sh | $17.23 | $168,526.63 | −4.8% | |
Mike OuimetteGeneral Counsel & Corp. Sec'y | Pliant TherapeuticsPLRX | Open-market sale10b5-1 plan | 24/01/17 | 24/01/19 | 5,197 sh | $17.23 | $89,544.31 | −8.6% |